We found no statistically significant differences in UPDRS scores, plasma BDNF levels or H(1)-MRS measures. 3 key findings →
Participants: 119 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Thirty-four of the 37 patients were male with mean age at onset of 61.5 years for RBD and 68.1 years for cognitive decline. 5 key findings →
Participants: 37 Evidence: low
Full summary, score breakdown and related studies → Original source
47/100
We followed 65 patients with probable Alzheimer's disease, who were initially mildly to moderately impaired, with semiannual assessments of cognitive and functional performance for up to 4 years. 5 key findings →
Participants: 65 Evidence: low
Full summary, score breakdown and related studies → Original source
Neuropathologic etiologies of PPCD were Alzheimer disease (AD) (n = 13), AD plus Parkinson disease (n = 1), AD-Lewy body variant (n = 2), dementia with Lewy bodies plus progressive subcortical gliosis of Neumann (n = 1), corticobasal degeneration (n = 2), and prion-associated diseases: Creutzfeldt-Jakob disease (n = 1) and fatal familial insomnia (n = 1). 3 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep disruption, nightly restlessness, sundowning, and other circadian disturbances are frequently seen in Alzheimer's disease (AD) patients. 2 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source
Olfaction scores were lower in patients with mild cognitive impairment than in healthy comparison subjects. 5 key findings →
Participants: 45 Evidence: low
Full summary, score breakdown and related studies → Original source
The cause of progressive supranuclear palsy (PSP) is not known and has been little studied. 4 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
Most patients came from the community (43% home without help and 42% home with help compared with 14% in assisted living and 1% in a nursing home). 5 key findings →
Participants: 21 Evidence: low
Full summary, score breakdown and related studies → Original source
Although there was no difference in the microbial α-diversity among the three groups, patients with AD or MCI had increased β-diversity compared with healthy controls. 5 key findings →
Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
Missense mutations in the alpha-synuclein gene cause familial Parkinson's disease (PD), and alpha-synuclein is a major component of Lewy bodies (LBs) in sporadic PD, dementia with LBs (DLB), and the LB variant of Alzheimer's disease (AD). 3 key findings →
Participants: 65 Evidence: low
Full summary, score breakdown and related studies → Original source
In this study we used an in situ approach to identify the oxidized nucleosides 8-hydroxydeoxyguanosine (8OHdG) and 8-hydroxyguanosine (8OHG), markers of oxidative damage to DNA and RNA, respectively, in cases of Alzheimer's disease (AD). 1 key finding →
Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source
Caregivers in the combined family therapy and technology intervention experienced a significant reduction in depressive symptoms at 6 months. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Some studies have suggested that people with a high educational level have a lower risk of developing dementia compared to people with a low educational level. 4 key findings →
Participants: 1,022 Evidence: low
Full summary, score breakdown and related studies → Original source
Irritability, agitation, and aggression were documented in 81 patients (81%) an average of 10 months after diagnosis. 5 key findings →
Participants: 81 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The coexistence of cerebrovascular disease leading to deep white matter infarction and normal-pressure hydrocephalus has been noted previously in clinical studies, as both diseases can present with the triad of gait disturbance, dementia, and incontinence. 5 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source
(1) The overall sensitivity of the NINCDS-ADRDA criteria in diagnosing "probable" AD from 56 patients with cortical dementia (AD and FTD) was 0.93. 5 key findings →
Participants: 56 Evidence: low
Full summary, score breakdown and related studies → Original source
An alternative model, the multiple trace theory (MTT), suggests that the capacity of the MTL to recollect episodic memories is of a more permanent nature. 2 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma biomarkers of AD using the automated Lumipulse platform show good diagnostic performance in detecting Alzheimer's pathology in cognitively unimpaired subjects. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cross-sectional cerebrospinal fluid (CSF) levels of tau and amyloid (A) beta (beta) are of diagnostic importance for Alzheimer's disease (AD) and mild cognitive impairment (MCI). 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease CSF biomarkers 42 amino acid long amyloid-β peptide (Aβ1-42), total tau protein (T-tau), and tau protein phosphorylated at threonine 181 (P-tau181) are considered surrogate biomarkers of Alzheimer's disease pathology, and significantly improve diagnostic accuracy. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cerebrospinal fluid (CSF) biomarkers, such as Aβ(42), total-tau and phosphorylated-tau(181) reflect neuropathological changes of Alzheimer's disease (AD). 3 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
CSF susAβ levels are influenced by biological and technical factors, and may represent a marker of Aβ susceptible to lipoprotein-mediated clearance. 1 key finding →
Participants: 69 Evidence: low
Full summary, score breakdown and related studies → Original source
These results indicate that FS (p-tau231 and MMSE) has a strong potential to provide an early distinction between AD and VaD. 4 key findings →
Participants: 198 Evidence: low
Full summary, score breakdown and related studies → Original source
The p-tau181/Aβ42 ratio alone might reliably detect AD pathology in heterogeneous samples of patients suffering from different types of dementia. 1 key finding →
Participants: 526 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is traditionally considered irreversible. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →